Motexafin Gadolinium With Chemotherapy and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer
This study has been terminated.
Sponsor:
Pharmacyclics
Information provided by:
Pharmacyclics
ClinicalTrials.gov Identifier:
NCT00080028
First received: March 22, 2004
Last updated: May 4, 2007
Last verified: May 2007
Tracking Information | |
---|---|
First Received Date ICMJE | March 22, 2004 |
Last Updated Date | May 4, 2007 |
Start Date ICMJE | |
Primary Completion Date | |
Current Primary Outcome Measures ICMJE | |
Original Primary Outcome Measures ICMJE | |
Change History | Complete list of historical versions of study NCT00080028 on ClinicalTrials.gov Archive Site |
Current Secondary Outcome Measures ICMJE | |
Original Secondary Outcome Measures ICMJE | |
Current Other Outcome Measures ICMJE | |
Original Other Outcome Measures ICMJE | |
Descriptive Information | |
Brief Title ICMJE | Motexafin Gadolinium With Chemotherapy and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer |
Official Title ICMJE | Phase I Trial of Motexafin Gadolinium and Chemoradiation in Locally Advanced, Squamous Cell Carcinoma of the Head and Neck |
Brief Summary | The purpose of this study is to evaluate the safety of adding the investigational drug Motexafin Gadolinium to the standard treatment of radiation therapy and chemotherapy with drugs called 5-FU and cisplatin in patients with advanced head and neck cancer. |
Detailed Description | |
Study Type ICMJE | Interventional |
Study Phase | Phase 1 |
Study Design ICMJE | Allocation: Non-Randomized Endpoint Classification: Safety Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
Condition ICMJE |
|
Intervention ICMJE | Drug: Motexafin Gadolinium Injection |
Study Arm (s) | |
Publications * | |
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|
Recruitment Information | |
Recruitment Status ICMJE | Terminated |
Enrollment ICMJE | 18 |
Completion Date | |
Primary Completion Date | |
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria: Laboratory Values of:
and
|
Gender | Both |
Ages | 18 Years and older |
Accepts Healthy Volunteers | No |
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects |
Location Countries ICMJE | United States |
Administrative Information | |
NCT Number ICMJE | NCT00080028 |
Other Study ID Numbers ICMJE | PCYC-0210 |
Has Data Monitoring Committee | |
Responsible Party | |
Study Sponsor ICMJE | Pharmacyclics |
Collaborators ICMJE | |
Investigators ICMJE | |
Information Provided By | Pharmacyclics |
Verification Date | May 2007 |
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |